Matrix metalloproteinase inhibitors.

Y, Zhang

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2010

Data sources: Europe PubMed Central

Matrix metalloproteinase inhibitors.

descriptionPublicationkeyboard_double_arrow_right Article 09 Jun 2010 English Journal:IDrugs : the investigational drugs journal, volume 1 (issn: 1369-7056,

Copyright policy )

Authors: Y, Zhang;

pmid: 18465633

Matrix metalloproteinase inhibitors.

- Summary
- Metrics

Abstract

The Division of Medicinal Chemistry offered a number of sub-sessions including this one on matrix metalloproteinase (MMP) inhibitors. The overexpression of matrix metalloproteinases has been associated with cancer malignancy, arthritis and several immune system-related infectious diseases such as sepsis. Encouraged by the impressive clinical trials of batimastat and marimastat (Figure 1; British Biotech plc), interest in MMP inhibitors has grown.

Related Organizations

University of Wisconsin–Oshkosh
United States

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average